PDCD1 and glioblastoma: These features of glioblastoma biology may partially explain why PD-1-based immunotherapy has failed to enhance survival in glioblastoma patients, along with other factors such as glioblastoma’s highly immunosuppressive microenvironment and/or poor T cell infiltration [39,40,41].